巴曲抗栓酶对肺原性心脏病病人血心钠素含量的影响

Effect of batroxobin (DF_521) on plasma level of atrial natriuretic peptides in patients with pulmonary heart disease

目的 :研究巴曲抗栓酶对肺原性心脏病病人血中心钠素 (ANP)含量的影响。方法 :对照组 15例(男性 10例 ,女性 5例 ;年龄 56±s 5a)接受常规治疗 (包括吸氧 ,抗生素及平喘药 ) ,巴曲抗栓酶组 15例 (男性 11例 ,女性 4例 :年龄 55± 7a)除接受常规治疗外静脉滴注巴曲抗栓酶 5BU ,加入 0 .9%氯化钠注射液 2 50mL ,每周 2次 ,共 2wk。结果 :治疗结束后巴曲抗栓酶组中ANP的含量低于对照组 (P<0 .0 5)。结论

AIM: To study the effect of batroxobin (DF_521) on the plasma level of atrial natriuretic peptides (ANP) in patients with pulmonary heart disease. METHODS: The control group, patients (M 10, F 5; age 56±s 5 a) received conventional therapy (including oxygen, antibiotics, and bronchodilators). The batroxobin (DF_521) group patients (M 11, F 4; age 55±7 a) received conventional therapy and batroxobin (DF_521) 5 BU in 0.9% saline injection 250 mL, iv drip, twice_weekly, for 2 wk. RESULTS: The level of ANP in batroxobin (DF_521) group was lower than that in control group at the end of treatment (P<0.05). CONCLUSION: Batroxobin(DF_521) improves heart function in patients with pulmonary heart disease.